Am Heart J:急性心衰初始推注利尿剂有益

2012-11-07 Am Heart J Am Heart J

  美国学者的一项研究表明,应用较大剂量利尿剂的急性心衰患者病情更为严重,并且可能从初始推注策略中获益。论文于2012年10月31日在线发表于《美国心脏杂志》(Am Heart J)。   DOSE-AHF研究共纳入308例入院24小时以内的急性心衰患者,并通过持续输注或推注方式随机给予大、小剂量静脉用利尿剂。此项研究以接受大(≥120 mg等量呋塞米,177例)、

  美国学者的一项研究表明,应用较大剂量利尿剂的急性心衰患者病情更为严重,并且可能从初始推注策略中获益。论文于2012年10月31日在线发表于《美国心脏杂志》(Am Heart J)。

  DOSE-AHF研究共纳入308例入院24小时以内的急性心衰患者,并通过持续输注或推注方式随机给予大、小剂量静脉用利尿剂。此项研究以接受大(≥120 mg等量呋塞米,177例)、小(<120 mg等量呋塞米,131例)剂量门诊利尿剂治疗的患者为受试者;对受试者基线特征进行对比,并对应用模式(持续或推注)和患者转归进行相关性评估。

  结果显示,大剂量呋塞米组患者应用肾素-血管紧张素系统抑制剂的频率较低,肾功能较差,并且晚期症状更多。对肌酐和强化策略进行校正之后,就72小时净液体丢失而言门诊用药剂量和治疗模式之间存在显著相互作用。住院时利尿剂用量与死亡和60天时再住院风险升高显著相关(P=0.03)。

  链接:

  Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from Diuretic Optimization Strategies in Acute Heart Failure



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1271917, encodeId=23a712e1917a2, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355693, encodeId=d0f91355693c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359767, encodeId=be351359e67d4, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562109, encodeId=dd4d15621097c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1271917, encodeId=23a712e1917a2, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355693, encodeId=d0f91355693c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359767, encodeId=be351359e67d4, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562109, encodeId=dd4d15621097c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-11-09 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1271917, encodeId=23a712e1917a2, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355693, encodeId=d0f91355693c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359767, encodeId=be351359e67d4, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562109, encodeId=dd4d15621097c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1271917, encodeId=23a712e1917a2, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355693, encodeId=d0f91355693c9, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359767, encodeId=be351359e67d4, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562109, encodeId=dd4d15621097c, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Nov 09 01:04:00 CST 2012, time=2012-11-09, status=1, ipAttribution=)]
    2012-11-09 slcumt

相关资讯

Am Heart J:高龄男性慢性心衰患者补充睾酮有益健康转归

  英国学者的一项研究首次表明,高龄慢性心衰患者于运动康复期间补充睾酮具有可行性,并且可对关键性健康转归产生积极影响。论文于2012年10月31日在线发表于《美国心脏杂志》(Am Heart J)。   此项研究共纳入41例睾酮水平较低的慢性心衰老年患者,并在运动康复基础上随机给予睾酮补充或安慰剂治疗。通过入组情况、干预顺应性和脱失情况评估可行性。转归包括往返步行试验增量、最

EHJ:大部分心脏病女性患者可安全度过妊娠期

  一项最新国际注册研究显示,尽管心脏病类型和地域上的差异可导致预后出现明显不同,但大部分心脏病女性患者可安全度过妊娠期。   这项欧洲妊娠与心脏病注册研究纳入2008~2011年6月28个国家60家医院收治的1,321例结构性或缺血性心脏病妊娠患者。患者的中位年龄为30岁(16~53岁),中位妊娠时间为38周,56%此前曾有≥1次妊娠,54%此前曾接受至少1次心脏干预。50例来自美国。大部分(

2012 HFSA年会:干预抑郁症可降低心衰死亡率

  西雅图——美国心力衰竭学会(HFSA)2012年会上公布的一项随机研究显示,注重预防和管理抑郁的认知生物行为干预可减少心力衰竭的不良结局。   在这项研究中,肯塔基大学护理学院院长Debra K. Moser教授及其同事纳入278例已接受稳定剂量药物治疗至少1个月、在过去3个月内未发生心肌梗死或卒中且无任何认知功能障碍的心力衰竭患者,分成3组:生物行为干预组(同时实施认知行为治疗和生物反馈放

HFSA2012:干预抑郁症可降低心力衰竭的不良后果

Debra K. Moser教授     美国心力衰竭学会(HFSA)2012年会上公布的一项随机研究显示,注重预防和管理抑郁的认知生物行为干预可减少心力衰竭的不良结局。     在这项研究中,肯塔基大学护理学院院长Debra K. Moser教授及其同事纳入278例已接受稳定剂量药物治疗至少1个月、在过去3个月内未发生心肌梗死或卒中

ACCF/AHA/HRS发布2012版心律失常器械治疗指南

  美国心脏病学会基金会(ACCF)、美国心脏学会(AHA)和美国心律协会(HRS)近日联合发布了《2012版心律失常器械治疗指南》,对收缩性心力衰竭患者的心脏再同步化治疗(CRT)作了较多更新(表)。9月10日,新版指南同时在线发表于《美国心脏病学会杂志》(J Am Coll Cardiol)、《循环》(Circulation)、《美国心胸外科杂志》(J 

Circulation:右心室肥大或增加心衰和死亡风险

近日,刊登在国际著名杂志Circulation上的一项研究报告中,来自宾夕法尼亚大学的研究者表示,增厚心脏的右心室和病人高风险的心力衰竭以及心血管死亡率(除临床的心血管疾病)直接相关。 很多研究中,研究者都着重研究于易于成像的心脏左心室,左心室是心脏的一块受全身性的高血压和其它常见状况所影响的区域。医学博士Steven Kawut表示,但是我们也应该重点关注右心室,因为很多心脏和肺部的疾病都和右